
Design Therapeutics, Inc.
DSGNNasdaqCIK 1807120HealthcareFiscal year ends Dec 31
Reports and events: 76 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2022-12-2216:25 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-22-311061 |
| 2022-11-0316:16 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-021885 |
| 2022-11-0316:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-021862 |
| 2022-08-0816:12 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-015533 |
| 2022-08-0816:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-015520 |
| 2022-06-1616:25 ET | 8-K | 5.07 Shareholder vote results | 0000950170-22-011751 |
| 2022-05-0916:14 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-008500 |
| 2022-05-0916:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-008486 |
| 2022-04-2716:25 ET | DEF 14A | Proxy statementPeriod 2022-06-15 | 0001193125-22-123683 |
| 2022-03-3116:23 ET | SC 13D | Ownership report, active investor | 0000935836-22-000298 |
| 2022-03-2216:36 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-22-004311 |
| 2022-03-1016:17 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-003369 |
| 2022-03-1016:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-003356 |
| 2021-11-0916:16 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-003753 |
| 2021-11-0916:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-21-003747 |
| 2021-08-2008:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-252071 |
| 2021-08-0917:18 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-042734 |
| 2021-08-0916:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-042617 |
| 2021-08-0616:31 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-239304 |
| 2021-06-0716:26 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001564590-21-031964 |
| 2021-05-1016:16 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-026062 |
| 2021-05-1016:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-026050 |
| 2021-04-0915:38 ET | SC 13D | Ownership report, active investor | 0001193125-21-111505 |
| 2021-03-3016:44 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-100253 |
| 2021-03-2206:11 ET | S-1/A | Registration statement, amended | 0001193125-21-088348 |
| 2021-03-0517:18 ET | S-1 | Registration statement | 0001193125-21-071667 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.